NHS England Expands Medical Cannabis Prescribing Guidance
NHS England has issued expanded guidance for specialist clinicians on prescribing unlicensed cannabis-based medicinal products (CBMPs), broadening the range of conditions where prescribing is considered appropriate. The updated framework acknowledges growing clinical evidence and aims to improve consistency across NHS trusts, potentially opening access to thousands more patients who have exhausted conventional treatment options.
NHS England Updates CBMP Prescribing Framework
NHS England has published revised guidance for specialist clinicians regarding the prescribing of cannabis-based medicinal products (CBMPs), marking a significant step forward for patients seeking access through the public healthcare system. The updated document, circulated to specialist commissioners and neurology, pain management, and psychiatry departments, broadens the clinical scenarios in which prescribing is deemed appropriate.
What the New Guidance Covers
The revised framework expands the conditions list beyond the three formally approved indications — childhood epilepsies, chemotherapy-induced nausea, and MS spasticity — to include guidance on evidence-based prescribing for treatment-resistant chronic pain, PTSD, and certain anxiety disorders. Crucially, it emphasises that consultants with relevant specialist qualifications may initiate CBMP prescriptions where standard treatments have failed.
The guidance also addresses shared care arrangements, enabling GPs to continue prescriptions initiated by specialists, which has historically been a barrier to ongoing access for patients.
Impact on Patients
For the estimated 1.8 million people in the UK living with chronic pain conditions poorly managed by conventional medicines, this represents meaningful progress. Campaigners have long argued that NHS access has been too restrictive, forcing patients towards private clinics at costs of £100 to £400 per month.
Patient advocacy organisations including the Medical Cannabis Clinicians Society (MCCS) welcomed the move, noting that clearer guidance should reduce the hesitancy among NHS consultants who have been reluctant to prescribe due to regulatory uncertainty.
Limitations Remain
The guidance stops short of mandating prescribing or removing cost barriers. CBMPs prescribed via the NHS remain subject to the standard prescription charge where applicable, but product costs are still typically borne by patients through pharmacy suppliers. NHS commissioning bodies have not yet confirmed additional funding for CBMP acquisition.
Private medical cannabis clinics continue to see strong demand as the fastest route to a legal prescription for most patients. Comparing clinic fees and prescription costs remains important — resources such as LeafMe can help patients evaluate their options before committing to a provider.
